Vorasidenib significantly improved median progression-free survival and time to next intervention in IDH-mutant grade 2 ...

A new Lancet Oncology Commission highlights a growing "human crisis" in cancer care. Despite advances in treatment and ...

"These longer-term results from the INDIGO trial build upon VORANIGO's previously demonstrated clinical benefits and ...

AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive bladder cancer ...

While AI advancements like 3D tumor auto-segmentation and radiation therapy planning have been FDA-approved for adult oncology, pediatric standards were lacking. The AI-RAPNO policy and its companion ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising effect in patients with active brain metastases of ...

An international clinical study led by the Medical University of Vienna shows that the drug patritumab deruxtecan (HER3-DXd) can have a promising ...

Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation ...

In 2015, the Lancet Commission on Global Surgery (LCoGS) demonstrated that 5 billion people lack adequate access to essential surgery, obstetric and anaesthesia care and set clear global targets for ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq ® ) versus regorafenib in patients ...

On Oct 8, 2025, a new law was introduced in British Columbia, Canada, that, if passed, will take action against e-cigarette ...